Actelion accelerates immunology push with MS drug trial

April 16, 2015 6:56 AM

22 0

April 16 (Reuters) - Actelion, Europe's biggest biotechnology company, is accelerating its push into immunology with the launch of late-stage tests of a drug for multiple sclerosis.

The Swiss group said on Thursday that it had initiated final Phase III development of ponesimod for relapsing multiple sclerosis and patients would be enrolled in a clinical trial imminently.

Also read: Kuwait says overnight fire at onshore oil rig now contained

Read more

To category page